April 20, 2006 15:11 ET

Spectrum Pharmaceutical Research Corporation Standardizes on OmniComm's TrialMaster® EDC Solution

FT. LAUDERDALE, FL -- (MARKET WIRE) -- April 20, 2006 -- OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that it has entered into a strategic partnership with Spectrum Pharmaceutical Research Corporation (www.spectrumcro.com), a Contract Research Organization (CRO) located in San Antonio, TX.

The TrialMaster® system, the core product of OmniComm Systems (www.omnicomm.com), provides Spectrum with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data. Founded in 1987, Spectrum has become a trusted clinical research partner to the pharmaceutical, biotech, and medical device industries. The most recent collaboration between OmniComm and Spectrum was initiated by a biopharmaceutical sponsor selecting the two companies for a planned Phase I study.

Spectrum's President, Toby Muligan, stated, "Having worked with OmniComm in the past, we knew they were the perfect match to satisfy our client's high level expectations in terms of service, price, and performance. Our client's trials often have very complex design requirements that go far beyond standard EDC implementation. As a CRO, OmniComm's TrialMaster solution offers us the best of both worlds in that we can deliver to our clients the functionality they desire at a price that offers outstanding value."

OmniComm System's CEO, Cornelis Wit, further stated, "OmniComm is pleased that Spectrum is a member of our growing list of CRO Partners. With special service packaging and pricing, CROs like Spectrum can now deliver trials deploying our TrialMaster EDC and trial management solution at lower prices than those run with paper forms. This is a win-win business model for all parties."

About OmniComm Systems, Inc.

OmniComm Systems, Inc. (www.omnicomm.com) is one of the fastest growing companies in the EDC market place targeting its product TrialMaster® to the pharmaceutical, medical device and biotechnology companies as well as CRO's. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employee's commitment to on-time, quality and within budget performance.

The TrialMaster (www.trialmaster.com) system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.